SNSS Sunesis Pharmaceuticals Inc.

1.17
+0.02  (+2%)
Previous Close 1.15
Open 1.15
Price To Book -4.68
Market Cap 79066362
Shares 67,578,087
Volume 485,929
Short Ratio
Av. Daily Volume 889,075

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 update due at EHA meeting June 13-16, 2019.
SNS-062
Advanced B-Cell Malignancies
Phase 2 investigator sponosored trial initiated March 2016
Vosaroxin in combination with cytarabine - VITAL
Previously untreated acute myeloid leukemia (AML) cancer
Phase 2 updated data released June 2016
Vosaroxin in combination with decitabine
Older patients with previously untreated acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) - cancer
Endpoint not met Oct 2014. Additional trials required.
Voreloxin
Cancer - Acute myeloid leukemia AML

Latest News

  1. Four Healthcare Stocks Heating Up on Thursday
  2. Sunesis Pharmaceuticals to Present at 18th Annual Needham & Company Healthcare Conference
  3. The Zacks Analyst Blog Highlights: Roche, Celgene, Johnson and Johnson, Bayer and Sunesis Pharmaceuticals
  4. 5 Cancer-Fighting Stocks to Boost Portfolio Gains
  5. Edison Issues Outlook on Sunesis Pharmaceuticals (SNSS)
  6. Will Sunesis Pharmaceuticals Continue to Surge Higher?
  7. Edited Transcript of SNSS earnings conference call or presentation 7-Mar-19 9:30pm GMT
  8. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
  9. Sunesis Pharmaceuticals to Participate in Upcoming Investor Conferences
  10. Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
  11. Sunesis Pharmaceuticals to Host Conference Call on March 7th to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Highlights
  12. Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
  13. Acorda (ACOR) Q4 Earnings and Revenues Surpass Estimates
  14. The Daily Biotech Pulse: Regulatory Roadblock For Immunomedics, AdCom Split On Lexicon's Diabetes Drug
  15. Sunesis Announces Pricing of $20 Million Offering of Securities
  16. Sunesis Announces Proposed Public Offering of Common Stock and Preferred Stock
  17. Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
  18. Edited Transcript of SNSS earnings conference call or presentation 5-Nov-18 9:30pm GMT
  19. The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
  20. Sunesis Pharmaceuticals Announces Presentation of Preliminary Data from Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies at ASH Annual Meeting